1221179-04-9

Basic information

• Product Name: Methyl 4-benzyloxy-2-fluorobenzoate
• Synonyms: Methyl 4-benzyloxy-2-fluorobenzoate
• CAS NO: 1221179-04-9
• Molecular Formula: C₁₅H₁₃FO₃
• Molecular Weight: 260.2603232
• Mol File: 1221179-04-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-benzyloxy-2-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-benzyloxy-2-fluorobenzoate(1221179-04-9)
• EPA Substance Registry System: Methyl 4-benzyloxy-2-fluorobenzoate(1221179-04-9)

Safety Data

• Hazardous Substances Data: 1221179-04-9(Hazardous Substances Data)

Upstream product

• 197507-22-5 methyl 2-fluoro-4-hydroxybenzoate 
• 100-39-0 benzyl bromide 

Downstream Products

• 1221179-07-2 tert-butyl 6-(benzyloxy)-3-methoxy-1H-indazole-1-carboxylate 
• 1221179-06-1 Tert-butyl 6-(benzyloxy)-3-oxo-2,3-dihydroindazole-1-carboxylate 

Relevant articles and documents

Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects

Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human β3-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant β3-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the α1A-AR (EC50 = 219 nM, selectivity: α1A/β3 = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for β3-AR agonistic activity versus α1A-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent β3-AR agonistic activity (EC50 = 13 nM) and high selectivity (α1A/β3 = >769-fold). Compound 11 was also inactive toward β1 and β2-ARs and showed dose dependent β3-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.

INDAZOLE ANALOGUE

[Objective] To provide a drug that selectively stimulates the β3-adrenergic receptors, particularly a drug capable of preferentially stimulating the β3-adrenergic receptors over the α1-adrenergic receptors. This drug can be used in the treatment and prevention of diabetes, obesity, hyperlipidemia, depression, cholelithiasis, diseases caused by biliary hyperkinesia, diseases caused by hyperfunction of the gastrointestinal tract, interstitial cystitis, overactive bladder or urinary incontinence, diseases associated with decreased lacrimation, and the like. [Solution] Indazole analogs represented by the general formula (I) or a salt thereof. Drugs that contains these indazole analogs or a salt thereof as the active ingredient.

INDAZOLE COMPOUNDS

Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.